This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Alphyn Biologics

Profile

Alphyn is using its AB-101 drug platform to develop safer, more effective therapeutics, initially for the $118 Billion Atopic Dermatitis (AD) market. After only 3½ years, Alphyn's first drug candidate, topical AB-101a, completed two Phase 2a clinical trials in AD with market-leading results, providing a faster path to regulatory approval and a huge commercial opportunity, with clinical results pointing to it being the "drug of choice" for this vast 800 million patient population.